High-risk AML evidenced by a monoclonal antibody
| Autor: | Niels Ebbe Hansen, Nis I. Nissen, S. Avnstrøm, E. Ralfkiær |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Poor prognosis Anticorps monoclonal medicine.drug_class Intensive chemotherapy Monoclonal antibody Subclass Antigen Bone Marrow medicine Humans Aged business.industry Antibodies Monoclonal Myeloid leukemia Hematology General Medicine Middle Aged Prognosis Surface membrane Leukemia Myeloid Acute Antigens Surface Immunology Female Blast Crisis business |
| Zdroj: | European Journal of Haematology. 41:156-162 |
| ISSN: | 1600-0609 0902-4441 |
| DOI: | 10.1111/j.1600-0609.1988.tb00885.x |
| Popis: | A monoclonal antibody has been raised against a surface membrane antigen present on leukemic myeloblasts. In 52 consecutive patients with acute myeloid leukemia treated in a standardized fashion with intensive chemotherapy the immunologic subclass with respect to this antigen was correlated to the clinical outcome. We found the expression of this antigen to predict a poor prognosis, when measured as survival of CR-patients and as survival after 1st relapse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text